Stock Analysis

Vaxart Full Year 2022 Earnings: Revenues Disappoint

Source: Shutterstock

Vaxart (NASDAQ:VXRT) Full Year 2022 Results

Key Financial Results

  • Net loss: US$107.8m (loss widened by 53% from FY 2021).
  • US$0.84 loss per share (further deteriorated from US$0.58 loss in FY 2021).
NasdaqCM:VXRT Earnings and Revenue History March 17th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Vaxart Revenues Disappoint

Revenue missed analyst estimates by 45%. Earnings per share (EPS) was mostly in line with analyst estimates.

Looking ahead, revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 3.7% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 5 warning signs for Vaxart (2 can't be ignored!) that you need to be mindful of.

What are the risks and opportunities for Vaxart?

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform.

View Full Analysis


  • Trading at 86.2% below our estimate of its fair value

  • Revenue is forecast to grow 68.19% per year


  • Has less than 1 year of cash runway

  • Makes less than USD$1m in revenue ($107K)

  • Shareholders have been diluted in the past year

  • Volatile share price over the past 3 months

  • Currently unprofitable and not forecast to become profitable over the next 3 years

View all Risks and Rewards

Share Price

Market Cap

1Y Return

View Company Report